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Abstract Clinical trials have shown the efficacy of
trastuzumab-based adjuvant therapy in HER2-positive
breast cancers, but routine clinical use awaits evaluation of
compliance, safety, and effectiveness. Adjuvant trast-
uzumab-based therapy in routine clinical use was evaluated
in the retrospective study GHEA, recording 1,002 patients
treated according to the HERA protocol between March
2005 and December 2009 in 42 Italian oncology depart-
ments; 874 (87.23 %) patients completed 1-year trast-
uzumab treatment. In 128 patients (12.77 %), trastuzumab
was withdrawn due to cardiac or non-cardiac toxicity (28
and 29 patients, respectively), disease progression (5
patients) or the clinician’s decision (66 patients). In
addition, 156 patients experienced minor non-cardiac tox-
icities; 10 and 44 patients showed CHF and decreased
LVEF, respectively, at the end of treatment. Compliance
and safety of adjuvant trastuzumab-based therapy in Italian
hospitals were high and close to those reported in the
HERA trial. With a median follow-up of 32 months, 107
breast cancer relapses were recorded (overall frequency,
10.67 %), and lymph node involvement, estrogen receptor
negativity, lymphoid infiltration, and vascular invasion
were identified as independent prognostic factors for tumor
recurrence, indicating that relapses were associated with
advanced tumor stage. Analysis of site and frequency of
distant metastases showed that bone metastases were sig-
nificantly more frequent during or immediately after
trastuzumab (\18 months from the start of treatment)
compared to recurrences in bone after the end of treatmentThis study was conducted on behalf of the GHEA group. The
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and wash-out of the drug ([18 months from the start of
treatment) (35.89 vs. 14.28 %, p = 0.0240); no significant
differences were observed in recurrences in the other
recorded body sites, raising the possibility that the pro-
tection exerted by trastuzumab is lower in bone metastases.
Keywords Breast cancer  HER2  Trastuzumab 
Adjuvant therapy  Distant metastasis
Introduction
The HER2 gene is amplified and/or overexpressed in
15–25 % of breast cancers and is associated with an
aggressive disease course [1–4]. Trastuzumab, a humanized
monoclonal antibody targeting the extracellular domain of
the transmembrane tyrosine kinase receptor HER2 [5], has
been shown in phase III clinical trials to reduce the risk of
relapse and death in patients with HER2-positive breast
cancers when administered along with chemotherapy in an
adjuvant setting [6–9]. Results of the Herceptin Adjuvant
(HERA) trial at 2 years of median follow-up showed that
1-year adjuvant trastuzumab treatment significantly
improved rates of disease-free survival (DFS) [hazard ratio
(HR) = 0.63, 95 % CI 0.53–0.75; p \ 0.0001) and overall
survival (HR = 0.63, 95 % CI 0.45–0.87; p = 0.0051) [10]
respect to observation group, with a significant benefit still
observed at 4-year [11] and 8-year [12] median follow-up.
These findings confirm that adjuvant trastuzumab given
sequentially to chemotherapy is associated with a persistent
benefit and remains an appropriate treatment modality in
patients with HER2-positive early breast cancer. However,
estimates provided by clinical trials for eligible patients may
not be entirely applicable to all women receiving trast-
uzumab-based therapy in community practice, pointing to
the need for observational studies as a tool to achieve a
complete picture of compliance and safety of trastuzumab-
based treatment.
The observational retrospective multicenter Italian study
GHEA (Group HErceptin in Adjuvant Therapy) was
designed to evaluate the adherence to trastuzumab treat-
ment guidelines and the safety of adjuvant trastuzumab in
Italian patients treated in routine clinical practice according
to the HERA protocol. Indeed, the protocol of the HERA
trial is a key reference for trastuzumab-containing che-
motherapy regimens in treating HER2-positive breast
cancer mainly carried out in an adjuvant setting in Europe,
including Italy. As an additional parameter to estimate
trastuzumab benefits in community practice, the GHEA
study also sought to determine whether patients relapsing
under trastuzumab treatment differ from those relapsing
after the end of the treatment with respect to prognostic
factors and site/frequency of distant metastases.
Patients and methods
Patients
The multicenter retrospective observational Italian study
GHEA included 1,002 HER2-positive breast cancer
patients treated with trastuzumab in an adjuvant setting in
42 Italian oncology departments from March 2005 to
December 2009. The database, closed on 16 December
2010, was examined in follow-up. Oncology departments
were recruited through a public call for Italian oncologic
centers treating at least 50 breast cancers/year and with
HER2-positive patients treated with adjuvant trastuzumab
from March 2005 to December 2009. Patients who were
considered eligible for adjuvant trastuzumab by the
oncologist and receiving this treatment for at least one
cycle in the indicated period were included. All primary
tumors were scored 3? by immunohistochemistry or 2?/
FISH-positive prior to trastuzumab treatment in each
institution. As in the HERA trial, trastuzumab was
administered, mainly every 3 weeks, in patients with pri-
mary breast cancer following surgery, chemotherapy
(neoadjuvant and/or adjuvant), and radiotherapy (if appli-
cable). Histopathological data, chemotherapy treatments,
type of surgery, site of first relapse, and times of relapse
were recorded for each patient. Non-cardiac toxicity data,
including haematological, gastrointestinal, respiratory,
renal, liver, dermatological, neurological, and infective
adverse events, as well as trastuzumab-associated cardio-
toxicity, including congestive heart failure (CHF), decrease
in LVEF, and alteration of conduction or pace, were reg-
istered. Adverse events were assessed clinically and by
haematological and biochemical means throughout the
treatment in each participating center. Cardiac function
was monitored in all patients every 4 months by electro-
cardiogram, and LVEF was assessed by echocardiography
or multiple gate acquisition (MUGA) scan. LVEF decrease
of C10 percentage points from baseline to \50 % at any
time was considered as adverse event. Breast cancer first-
relapse events were registered as local, contralateral, or
distant when they occurred, respectively, in the same breast
as the first tumor, in the other breast, or in another part of
the body [central nervous system (CNS), bone, liver, lung,
visceral, lymph nodes, and other organs]. For patients with
multiple synchronous sites of recorded events, the first-
relapse site was hierarchically considered as distant, local,
contralateral breast cancer, and second primary malignan-
cies. Non-breast second primary tumors were considered as
‘‘other neoplasia’’. Relapses were subgrouped either as
‘‘early’’ when they occurred during the 1-year trastuzumab
treatment and in the next 6 months or ‘‘late’’ when they
occurred after the 18 months. DFS was defined as the time
from start of trastuzumab treatment to the first event.
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To ensure rapid and homogeneous data-gathering for
patients enrolled in the study, a web-based system was
specifically developed to record patient clinical and
demographical data. Structured forms for data entry using
the Microsoft SQL server and with exclusive log-in and
password for Internet access to insert and update all data by
each participating center were created. The database was
accessible to a single administrator who supervised and
monitored data accrual in each center since the beginning
of the project. At the end of the data entry period, access to
the system was restricted for all participating centers. The
Independent Ethics Committee of each participant institu-
tion approved the observational study.
Statistical analysis
Bivariate analysis was carried out for all variables with
respect to relapses, using contingency tables evaluated by
Chi square or Fisher’s exact test. DFS analysis was carried
out based on the life-table method [13] including any types
of relapses.
Univariate analysis was carried out using the phreg SAS
procedure with univariate Cox proportional hazards
regression. All predictors with p \ 0.05 were used in
multivariate analysis with backward elimination, using the
Cox regression model and evaluated by Chi square test.
Assumption of proportionality was tested for all covariates
by including time-dependent covariates in the model using
the interaction with log(time). All analyses were conducted
using SAS software (SAS Institute Inc., Cary, NC). Two-
sided p \ 0.05 was considered significant.
Results
We analyzed data from 1,002 HER2-positive breast cancer
patients treated with trastuzumab in an adjuvant setting.
Table 1 lists the characteristics of patients and disease. The
median age was 52.9 years, 45.01 % of patients were node-
negative, 44.01 % were both ER- and PgR-positive, and
17.16 % were positive for one of the two hormone recep-
tors, and 53.69 % had T1 tumor size (54.85 % of T1
tumors were node-negative). As expected for HER2-posi-
tive carcinomas, tumors were mainly grade III (59.99 %)
and of ductal histotype (85.43 %). All patients were treated
with chemotherapy: 182 received neoadjuvant treatment,
n = 1002
HER2-positive breast cancer patients trastuzumab-treated in adjuvant setting between 2006-2009
Follow-up until December 2010
116 recorded any first progression of disease
9 second neoplasia
107 breast cancer relapses
18 local and 1 contralateral
88 distant metastases
Endpoint: Analysis of compliance and safety of trastuzumab-based  setting
39 occured between  18 months 
from trastuzumab start
49 occured after  18 months 
from trastuzumab start
Comparison of the prognostic factors an d frequency of first distant metastases in two subgroups
Fig. 1 CONSORT diagram of
the Italian retrospective study
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862 received adjuvant treatment, and 42 both. Chemo-
therapy was mostly anthracycline-based (84.33 %) and
45.41 % of these patients also received taxanes. Hormone
therapy was used in 54.99 % of patients, 60.44 %of whom
received aromatase inhibitors. Almost all recorded patients
(97.80 %) underwent trastuzumab administration every
3 weeks, with 1-year trastuzumab treatment completed in
874 (87.23 %) patients. Of 128 patients (12.77 %) who
discontinued trastuzumab, 123 stopped for reasons other
than relapse and 5 for relapse during therapy. Treatment
withdrawal was due to cardiac and non-cardiac adverse
events in 28 (20 for CHF and 8 for decreased LVEF), and
29 patients (10 for dermatological, 6 for haematological, 4
for gastrointestinal, 4 for neurological, 2 for infective, 1 for
renal, 1 for liver, and 1 for respiratory adverse events),
respectively, and to clinical judgment in 66 (Table 2).
Toxicity was the most relevant factor leading to trast-
uzumab withdrawal in patients treated for \6 months,
while the clinical decision was the major motivation to stop
treatment in those who received trastuzumab for C6 but
\12 months (Table 2). Of note, 80.36 % of these patients
had T1 and/or N0 tumors. In addition, 156 patients expe-
rienced minor non-cardiac toxicities; of 701 patients who
were monitored for cardiac toxicities past the end of
Table 1 Baseline patient and tumor characteristics of 1,002 GHEA
study patients
Characteristics No. (%)
Age
\35 years 35 (3.49)
35–49 years 358 (35.72)
50–59 years 303 (30.23)
[60 years 297 (29.64)
Missing 9 (0.89)
Median age* 52.9 (26–81)
Menopause
Yes 488 (48.70)
No 298 (29.75)
Uncertain 33 (3.29)
Missing data 183 (18.26)
Nodal status
N- 451 (45.01)
N? 522 (52.1)
Nx 14 (1.39)
Missing data 15 (1.50)
Tumor size
T1 538 (53.69)
T2 351 (35.03)
CT3 94 (9.38)
Missing data 19 (1.90)
Histological grade
III 601 (59.99)
II 323 (32.23)
I 13 (1.29)
Missing data 65 (6.49)
HER2 status
HER2-positive 3? 834 (83.23)
HER2-positive 2?/FISH amplified 168 (16.77)
Hormone receptor status
ER-/PgR- 377 (37.63)
ER-/PgR? 28 (2.79)
ER-/PgR unknown 2 (0.2)
ER?/PgR? 441 (44.01)
ER?/PgR- 133 (13.27)
ER?/PgR unknown 10 (1.0)
ER unknown/PgR unknown 10 (1.0)
ER unknown/PgR? 1 (0.10)
Surgery for primary tumors
Mastectomy 406 (40.51)
Quadrantectomy 552 (55.09)
Lumpectomy 32 (3.19)
Missing data 12 (1.20)
Histological type
Ductal 856 (85.43)
Lobular 52 (5.19)
Mixed 25 (2.50)
Table 1 continued
Characteristics No. (%)
Other 63 (6.28)
Missing data 6 (0.6)
Therapy
Neoadjuvant or adjuvant chemotherapy
No anthracyclines 157 (15.67)
Anthracyclines-no taxanes 390 (38.92)
Anthracyclines-taxanes 455 (45.41)
Hormone therapy
Yes 551 (54.99)
Aromatase inhibitors 333/551 (60.44)
Tamoxifen 218/551 (39.56)
Trastuzumab
Every 3 weeks 980 (97.80)
Weekly 18 (1.80)
Unspecified time of administration 4 (0.40)
Time of trastuzumab treatment
1-year 874 (87.23)
From C9 to \12 months 18 (1.80)
From C6 to \9 months 73 (7.28)
From C3 to \6 months 21 (2.09)
Less than 3 months 16 (1.60)
* Data are given as year (range)
N axillary lymph nodes, T tumor size, ER estrogen receptor, PgR
progesterone receptor
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treatment, 10 and 44 patients showed CHF and decreased
LVEF, respectively. In the entire series, LVEF was moni-
tored by MUGA in only 20 patients. Non-cardiac toxicities
included haematological, gastrointestinal, respiratory, renal,
liver, dermatological, and neurological adverse events.
With a median follow-up of 32 months, 107 (10.68 %)
breast cancer events, including local (1.80 %), contralateral
(0.10 %), and distant recurrences (8.78 %), were registered
(Table 3; Fig. 1). In addition, 9 (0.90 %) secondary non-
breast primary tumors were observed (one thyroid, one
lung, one renal, two endometrial, one leukemia, and three
unspecified carcinomas). Figure 2 shows the DFS of our
series calculated from the start of trastuzumab treatment.
When breast cancer relapse occurring after the end of the
treatment was analyzed according to time of trastuzumab
treatment, five (13.51 %) recurrences were observed in 37
patients treated \6 months, 6 (6.59) in 91 patients treated
from C6 to\12 months, and 74 (8.47) in 874 patients who
completed the 1-year treatment.
Analysis of the clinical and pathological characteristics
listed in Table 1 revealed an association between tumor
recurrence and axillary lymph node involvement (N?)
(p \ 0.0001), larger tumor size (p \ 0.0001), absence of
estrogen receptors (p \ 0.0001), and of progesterone
receptors (p = 0.0018), vascular invasion (p = 0.0005),
lymphoid infiltration (p = 0.0023), grade III (p = 0.0026),
and chemotherapy regimens (p = 0.0024) (Table 4). Uni-
variate analysis indicated that lymph node involvement,
grade III, larger tumor size, lymphoid infiltration, vascular
invasion, absence of hormone receptors, and treatment with
anthracyclines plus taxanes were significantly associated
(p \ 0.05) with DFS (Table 5). A positive significant
correlation of the anthracyclines plus taxanes regimen was
observed with size and node positivity (p \ 0.0001),
indicating that patients with more advanced tumors
received this therapeutic regimen. Multivariate analysis of
covariates displaying p \ 0.05 identified lymph node
involvement (HR = 3.633, 95 % CI 1.600–8.249,
p = 0.0020), presence of estrogen receptors (HR = 0.552,
95 % CI 0.314–0.968, p = 0.0382), lymphoid infiltration
(HR = 1.912, 95 % CI 1.061–3.444, p = 0.0310), and
vascular invasion (HR = 1.853, 95 % CI 1.028–3.338,
p = 0.0400) as independent prognostic factors (Table 5).
Comparison of ‘‘early’’ recurrences (44 cases, including
five local relapses) arising during or immediately after
trastuzumab treatment (B18 months from start of treat-
ment) and ‘‘late’’ recurrences (63 relapses, including 13
local and 1 contralateral recurrences) occurring after the
end of the treatment and wash-up of the drug ([18 months
from start of treatment) revealed no significant differences
in clinical and pathological parameters (Table 6).
Table 2 Treatment compliance
Time of trastuzumab
treatment
No. of
cases
% Reasons for withdrawal
Progression
N (%)
Cardiac
toxicities
N (%)
Non-cardiac
toxicities
N (%)
Clinical
decision
N (%)
Less than 3 months 16 1.60 0 9 (56.25) 5 (31.25) 2 (12.50)
From C3 to \6 months 21 2.09 1 (4.76) 8 (38.10) 4 (19.04) 8 (38.10)
From C6 to \9 months 73 7.28 4 (5.48) 10 (13.70) 18 (24.66) 41 (56.16)
From C9 to \12 months 18 1.80 0 1 (5.55) 2 (11.11) 15 (83.34)
1 year 874 87.23 – – – –
Total 1,002 100 5 (0.49) 28 (2.79) 29 (2.89) 66 (6.58)
Table 3 First recorded events
Events No. (%)
n = 1,002
Other neoplasia 9 (0.90)
Breast carcinoma events 107 (10.70)
Local 18 (1.80)
Contralateral 1 (0.10)
Distant metastases 88 (8.78)
n. at risk 1002 884 678 343 69
Fig. 2 Disease-free survival from date of first trastuzumab treatment
in HER2-positive patients treated in an adjuvant setting
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In our series, bone (23.86 %) was the most frequent site
of first distant metastasis, followed by CNS (17.05 %).
Notably, comparison of the frequency of first distant
metastases in the two subgroups (39 early vs. 49 late distant
metastases) according to site (Table 7) indicated a signifi-
cantly higher rate of bone metastases in early than in late
recurrences (35.89 vs. 14.28 %, p = 0.0240) and a higher,
although not statistically significant, incidence of CNS
relapses (23.07 vs. 12.24 %). Metastases in the late versus
early group were not significantly more frequent in liver
(16.32 vs. 10.26 %), lung (18.37 vs. 10.26 %), other vis-
cera (6.12 vs. 0.00 %), or lymph nodes (16.32 vs. 7.69 %);
cases with multiple relapses at the time of diagnosis were
equally distributed in the two subgroups (14.28 % in early
vs. 10.26 % in late metastases).
Discussion
The observational study GHEA shows that trastuzumab
treatment is feasible and well-tolerated in routine clinical
practice. Indeed, the majority of the patients recorded in
the study adhered to trastuzumab administration following
locoregional treatment and chemotherapy as in the HERA
trial, with injection every 3 weeks in 97.80 % of them and
completion of the 1-year trastuzumab therapy in 874
Table 4 Baseline
characteristics of non-relapsed
or relapsed breast cancer
patients
For missing data for each
variable, see Table 1. Second
non-breast primary tumors were
excluded
ER estrogen receptor, PgR
progesterone receptor, T tumor
size, N axillary lymph nodes
a Fisher’s exact test or Chi
square test
Parameters Non-relapsed Relapsed pa
Age (year) 53 (26.81) 52 (30.80) –
Postmenopause (no./total, %) 428/695 (61.58) 53/83 (63.85) 0.7213
ER-neg (no./total, %) 343/875 (39.20) 63/107 (58.90) \0.0001
PgR-neg (no./total, %) 436/868 (50.23) 70/105 (66.7) 0.0018
Tumor size (no./total, %)
T1 496/870 (57.01) 36/104 (34.61) \0.0001
T2 305/870 (35.06) 42/104 (40.38)
CT3 68/870 (7.81) 26/104 (25.00)
Vascular invasion (no./total, %) 220/655 (33.60) 43/80 (53.75) 0.0005
Lymphoid infiltration (no./total, %) 204/587 (34.75) 38/70 (54.28) 0.0023
Necrosis (no./total, %) 193/637 (30.30) 29/75 (38.67) 0.1481
Grade III (no./total, %) 518/830 (62.41) 77/99 (77.78) 0.0026
N? (no./total, %) 448/873 (51.32) 81/105 (77.14) \0.0001
Chemotherapy
Anthracyclines-no taxanes 365/886 (41.20) 29/107 (27.10)
Anthracyclines-taxanes 375/886 (42.33) 64/107 (59.81) 0.0024
No anthracyclines 146/886 (16.48) 14/107 (13.08)
Table 5 Univariate and multivariate analyses of parameters for disease-free survival (DFS) in 1,002 patients
Parameters Univariate analysis Multivariate analysis
HR 95 % CI p HR 95 % CI p
Lymph nodes (pos vs. neg) 2.839 1.800–4.478 \0.0001 3.633 1.600–8.249 0.0020
Grade (III vs. II/I) 2.019 1.257–3.243 0.0037
ER (pos vs. neg) 0.467 0.317–0.686 0.0001 0.552 0.314–0.968 0.0382
PgR (pos vs. neg) 0.533 0.355–0.799 0.0023
Size ([T1 vs. BT1) 2.286 1.526–3.425 \0.0001
Menopause (yes vs. no) 1.144 0.731–1.791 0.5566
Necrosis (yes vs. no) 1.433 0.900–2.280 0.1296
Lymphoid infiltration (yes vs. no) 2.351 1.468–3.765 0.0004 1.912 1.061–3.444 0.0310
Vascular invasion (yes vs. no) 2.172 1.400–3.372 0.0005 1.853 1.028–3.338 0.0400
Anthracycline-taxanes vs. anthracycline-no taxanes 2.452 1.484–4.058 0.0005
No anthracycline vs. anthracycline- no taxanes 1.719 0.846–0.0494 0.1345
HR hazard ratio, p Chi square test
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(87.23 %) patients. The treatment discontinuation rate was
higher in our series than in the HERA trial [6, 10] due to
6.587 % of patients who stopped trastuzumab not for tox-
icity but for clinical and/or patient decision, while the
frequency of adverse events accounting for trastuzumab
withdrawal was similar to that in the HERA trial.
While toxicities were the major reason for treatment
withdrawal within 6 months, later withdrawal reflected the
clinician’s judgment that for patients at low risk of recur-
rence, the risk of adverse cardiac events could be mini-
mized by reducing the treatment length without
compromising efficacy. Indeed, less than 1-year of trast-
uzumab is reportedly active in decreasing relapse rates [8].
Consistent with this hypothesis, of the 56 patients who
stopped the treatment based on the clinician’s decision,
80.36 % had T1 and/or N0 tumors. The low aggressiveness
of these carcinomas is also demonstrated by the lower
frequency of relapses after withdrawal compared with
patients who stopped before 6 months of treatment. The
decision against completing 1-year trastuzumab treatment
is still rare and, in fact, was made for only about 7 % of the
patients in Italian clinical practice.
Trastuzumab was withdrawn due to cardiac events in 28
patients (2.79 %), a rate similar to that in the HERA trial [14,
15]. However, another 54 patients experienced cardiac tox-
icity after the end of treatment, consistent with a recent
population-based observational study [16] reporting that the
risk of cardiotoxicity associated with trastuzumab following
anthracycline appears to increase over time. This under-
scores the need for long-term surveillance of cardiotoxicity.
Since trastuzumab followed anthracycline-based regimens
in the majority of patients, clinical practice should include
cardiac monitoring past the end of treatment.
We observed that patients treated with adjuvant trast-
uzumab in the Italian clinical practice were at an earlier
stage of disease compared with those included in the
Table 6 Baseline
characteristics of relapsed
patients according to the time of
relapse
a Fisher’s exact test or Chi
square test
Parameters Early recurrences
(0–18 months)
n = 44
Late recurrences
([18 months)
n = 63
pa
Age (year, range) 52 (30–75) 51 (32–80)
Postmenopause (no./total, %) 18/29 (62.07) 35/54 (64.81) 0.8150
ER-neg (no./total, %) 26/44 (59.09) 37/63 (58.73) 1
PgR-neg (no./total, %) 28/43 (65.12) 42/62 (67.74) 0.8348
Tumor size (no./total, %)
T1 20/43 (46.51) 16/61 (26.23)
T2 14/43 (32.56) 28/61 (45.90) 0.1005
CT3 9/43 (20.93) 17/61 (27.87)
Vascular invasion (no./total, %) 15/31 (48.39) 28/49 (57.14) 0.4952
Lymphoid infiltration (no./total, %) 18/33 (54.56) 20/37 (54.05) 1
Necrosis (no./total, %) 12/35 (34.28) 17/40 (42.50) 0.4872
Grade III (no./total, %) 32/40 (80.0) 45/59 (76.27) 0.8065
N? (no./total, %) 32/43 (74.42) 49/62 (79.03) 0.6400
Chemotherapy
Anthracycline-no taxanes 12/44 (27.27) 17/53 (26.98)
Anthracycline-taxanes 26/44 (59.09) 38/63 (60.32) 0.9877
No anthracyclines 6/44 (13.64) 8/63 (12.70)
Table 7 Metastatic sites of first
distant relapse in early and late
recurrences
a Data are given as number and
percent
b Fisher’s exact test or Chi
squared test
Site of distant relapse Earlya (0–18 months)
n = 39 (%)
Latea ([18 months)
n = 49 (%)
pb
Central nervous system 9 (23.07) 6 (12.24) 0.2545
Bone 14 (35.89) 7 (14.28) 0.0240
Liver 4 (10.26) 8 (16.32) 0.2927
Lung 4 (10.26) 9 (18.37) 0.3712
Visceral 0 (0) 3 (6.12) 0.2512
Lymph node 3 (7.69) 8 (16.32) 0.3333
Multiple 4 (10.26) 7 (14.28) 0.7484
Unspecified 1 (2.56) 1 (2.04) 1
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HERA trial. Overall, the 11 % of relapse events observed
in the GHEA study is similar to the 13 % reported in the
2-year median follow-up of HERA [10], considering the
earlier stage of disease of our patients. Recently published
results [17] derived from 87 patients treated with adjuvant
trastuzumab in a public hospital showed a compliance and
safety similar to that of our study and of the HERA trial,
further supporting the feasibility of this treatment outside
clinical trials.
Our analysis of the role of pathobiological markers in
increasing the risk of relapse suggests that the recurrences
in trastuzumab-treated patients in clinical practice are
associated with a more advanced stage of disease, consis-
tent with the progressively decreased dependence of more
advanced tumors on the HER2 signaling pathway [18].
Since maximum trastuzumab activity in clinical trials is
reportedly restricted to the time of treatment and a few
months thereafter [10], we hypothesize that relapses in this
period are ‘‘truly’’ resistant, while later relapses that might
have been sensitive when trastuzumab was present develop
upon antibody wash-out. Thus, assuming that early relapses
recorded in our study are associated with trastuzumab
resistance, we speculate that the pathobiologic parameters
analyzed are not involved in trastuzumab resistance since
their distribution was similar in early and late relapses.
This is consistent with other reports showing Forest plots
unable to identify parameters predictive of resistance and
useful in clinical practice; indeed, no association between
response to trastuzumab and hormone receptor status,
grade, node involvement, or size has been found [10, 11].
Notwithstanding the observational nature of our study
and the limited number of cases of relapses in our series,
we noted a significantly higher frequency of bone relapses
during the trastuzumab treatment as compared to recur-
rences at that site after the end of treatment and wash-out
of the drug. While the higher frequency of CNS metastatic
disease [19] is consistent with the inability of trastuzumab
to pass the blood–brain barrier and affect brain metastases
[20–22], the lower activity of trastuzumab in preventing
bone relapses should be of interest for clinicians to better
direct choice of therapies in these patients. Proof of the low
activity of trastuzumab in countering bone metastases
awaits analysis of bone relapses occurring during and after
trastuzumab treatment with respect to the observational
HERA patient population. If proven, the basis of this low
efficacy of trastuzumab on bone metastases warrants
analyses to estimate the drug’s penetration in this tissue,
although antibodies can localize in bone [23], or to confirm
in vivo the reduction of HER2 expression levels in tumor
cells homing to the bone, as reported in some studies ([24]
and references therein). These mechanisms might impair
both cytotoxic and cytostatic effects of trastuzumab
(reviewed in [4]), triggering resistance escape mechanisms
through upregulation of other receptor activities or through
perturbation of the bone microenvironment [25–27].
Our data pointing to low trastuzumab activity in bone
relapses are consistent with its higher activity on visceral
recurrences observed in the HERA trial with 1-year median
follow-up [6], i.e., during or immediately after trastuzumab
administration, and also at 4-year median follow-up, when
the best trastuzumab-induced benefits were observed for
liver recurrences [28].
Among other trials of trastuzumab in the adjuvant set-
ting, only PACS06 reported relapses according to site in
the randomized arms [29]; however, the lack of a statisti-
cally significant reduction in relapse risk by trastuzumab
observed in that study precludes comparison with our
results. Moreover, final overall survival analysis of the
EGF104900 trial, a phase III randomized multicenter open-
label study of lapatinib alone compared with lapatinib plus
trastuzumab in patients with HER2-positive metastatic
breast cancer, whose disease progressed during prior
trastuzumab therapy, showed that patients with visceral but
not those with bone disease significantly benefited from the
addition of trastuzumab to lapatinib treatment [30].
In conclusion, our data revealed high compliance of
adjuvant trastuzumab treatment in Italian oncology clinics, a
satisfactory trastuzumab safety profile, and a treatment
efficacy close to that observed in clinical trials. Our results
indicating a significantly higher frequency of bone metas-
tases in the first 18 months from the start of trastuzumab
treatment merit-specific future analyses to address the pos-
sibility that trastuzumab has low efficacy in bone metastases.
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